135380-50-6

Basic information

• Product Name: 2,7-Diazaspiro[3.5]nonane, 7-Methyl-
• Synonyms: 2,7-Diazaspiro[3.5]nonane, 7-Methyl-;7-Methyl-2,7-diazaspiro[3.5]nonane;7-Methyl-2,7-diazaspiro[3.5]nonane oxalate
• CAS NO: 135380-50-6
• Molecular Formula: C₈H₁₆N₂
• Molecular Weight: 140.22604
• Mol File: 135380-50-6.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 318.5°C at 760 mmHg
• Flash Point: 135.6°C
• Appearance: /
• Density: 1.07g/cm³
• Vapor Pressure: 0.00036mmHg at 25°C
• Refractive Index: 1.589
• Storage Temp.: 2-8°C
• PKA: 10.76±0.20(Predicted)
• CAS DataBase Reference: 2,7-Diazaspiro[3.5]nonane, 7-Methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 2,7-Diazaspiro[3.5]nonane, 7-Methyl-(135380-50-6)
• EPA Substance Registry System: 2,7-Diazaspiro[3.5]nonane, 7-Methyl-(135380-50-6)

Safety Data

• Hazardous Substances Data: 135380-50-6(Hazardous Substances Data)

Usage

General Description

2,7-Diazaspiro[3.5]nonane, 7-methyl- is a chemical compound with the molecular formula C9H19N2. It is a heterocyclic compound with a spirocyclic structure containing two nitrogen atoms. This chemical has potential applications in medicinal chemistry and pharmaceutical research due to its unique structure and potential biological activity. Its spirocyclic structure may confer specific binding properties, making it an interesting target for drug discovery and design. Further research and development of this compound may lead to the discovery of new therapeutic agents for various medical conditions.

InChI:InChI=1/C15H22N2/c1-16-12-15(13-16)7-9-17(10-8-15)11-14-5-3-2-4-6-14/h2-6H,7-13H2,1H3

Upstream product

• 157736-58-8 1-methyl-4-<<4-methylphenylsulfonyl>oxy>methyl-4-piperidinecarbonitrile 
• 20691-92-3 1-methylpiperidine-4-carbonitrile 
• 157736-50-0 4-hydroxymethyl-1-methyl-4-piperidinecarbonitrile 
• 1093066-77-3 7-methyl-2,7-diaza-spiro[3.5]nonane-2-carboxylic acid tert-butyl ester 
• 236406-55-6 2,7-diaza-spiro[3.5]nonane-2-carboxylic acid tert-butyl ester 
• 929301-99-5 tert-butyl 7-benzyl-2,7-diazaspiro[3.5]nonane-2-carboxylate 
• 929302-18-1 2-(tert-butoxycarbonyl)-2,7-diazaspiro[3.5]nonan-7-ium hydrochloride 

Relevant articles and documents

LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS

Provided herein are lipid compounds that can be used in combination with other lipid components, such as neutral lipids, cholesterol and polymer conjugated lipids, to form lipid nanoparticles for delivery of therapeutic agents (e.g., nucleic acid molecules) for therapeutic or prophylactic purposes, including vaccination. Also provided herein are lipid nanoparticle compositions comprising said lipids.

SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS

The present invention relates novel substituted nucleoside analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

PHARMACEUTICAL COMPOUNDS

Furanopyrimidines of formula (I): wherein W represents a furan ring; R1 and R2 form, together with the N atom to which they are attached, a group of the following formula (IIa): in which A is selected from: (a) a 4- to 7-membered saturated N-containing heterocyclic ring which includes 0 or 1 additional heteroatoms selected from N, S and O, the ring being fused to a second ring selected from a 4- to 7-membered saturated N-containing heterocyclic ring as defined above, a 5- to 12-membered unsaturated heterocyclic ring, a 5- to 7-membered saturated O-containing heterocyclic ring, a 3- to 12- membered saturated carbocyclic ring and an unsaturated 5- to 12- membered carbocyclic ring to form a heteropolycyclic ring system, the heteropolycyclic ring system being unsubstituted or substituted; (b) a 4- to 7-membered saturated N-containing heterocyclic ring which includes 0 or 1 additional heteroatoms selected from N, S and O and which further comprises, linking two constituent atoms of the ring, a bridgehead group selected from -(CR'2)n- and -(CR'2)r-O-(CR'2)s- wherein each R' is independently H or C1 - C6 alkyl, n is 1, 2 or 3, r is 0 or 1 and s is 0 or 1, the remaining ring positions being unsubstituted or substituted; and (c) a group of formula (IIb): wherein ring B is a 4- to 7-membered saturated N-containing heterocyclic ring which includes 0 or 1 additional heteroatoms selected from N, S and O and ring B' is a 3- to 12- membered saturated carbocyclic ring, a 5- to 7- membered saturated O-containing heterocyclic ring or a 4- to 7-membered saturated N-containing heterocyclic ring as defined above, each of B and B' being unsubstituted or substituted; m is 0, 1 or 2; R3 is H or C1-C6 alkyl; R4 is an indole group which is unsubstituted or substituted; and Ra is selected from R, halo, CN, C(O)NR2, halo(C1-C6)alkyl, SO2R, SO2NR2, NRSO2R, NRC(O)R, NRC(O)OR and NRC(O)NR2 wherein each R is independently H or C1-C6 alkyl; and the pharmaceutically acceptable salts thereof are inhibitors of PI3K and are selective for the p110δ isoform, which is a class Ia PI3 kinase, over both other class Ia and class Ib kinases. The compounds may be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.